Sign in
AVDL Stock Price, Chart, Stats & News
Avadel Pharmaceuticals plc
Save
2.12B
Market cap
–
Current P/E
16.86x
Forward P/E
AVDL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 94.47% |
Operating margin | 1.82% |
Pretax margin | -1.31% |
Net margin | -0.11% |
Effective tax rate | 91.46% |
ROA | -0.14% |
ROE | -0.33% |
D/E | 0.38x |
Interest coverage ratio | 0.47x |
AVDL valuation
P/E | – |
P/S | 8.55x |
P/B | 21.39x |
P/CF | 59.03x |
P/FCF | 59.99x |
P/OCF | 59.03x |
PEG | -75.09x |
EV multiple | 213.86x |
About
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Similar securities
Based on sector and market capitalization
Report issue